Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genome engineering company Synthego raises $110mm in Series C round

Executive Summary

Synthego Corp. (genome engineering) raised $110mm in its Series C financing round led by Founders Fund along with returning backers 8VC and Menlo Ventures. The company's latest product line provides one-click access to engineered cells with guaranteed edits in desired targets. To date, Synthego has raised $160mm, with the current round proceeds to be used to accelerate CRISPR capabilities for rapid and precise genome engineering in cell and gene therapies. More specifically, the company will double down on its engineered cells and CRISPRevolution products, expand further into Europe and Asia, and continue extending its full stack genome engineering platform. Along with the funding, cell therapy pioneer Dr. Matthew Porteus joins the advisory board.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies